These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24382657)

  • 21. Recurrence after breast ablation for ductal carcinoma in situ.
    de Jong E; Peterse JL; van Dongen JA
    Eur J Surg Oncol; 1992 Feb; 18(1):64-6. PubMed ID: 1310646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR; Schwartz GF; Palazzo JP; Toll AD; Brill KL; Jaslow RJ; Lee SY
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting a local recurrence after breast-conserving therapy by gene expression profiling.
    Nuyten DS; Kreike B; Hart AA; Chi JT; Sneddon JB; Wessels LF; Peterse HJ; Bartelink H; Brown PO; Chang HY; van de Vijver MJ
    Breast Cancer Res; 2006; 8(5):R62. PubMed ID: 17069664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
    Macdonald HR; Silverstein MJ; Lee LA; Ye W; Sanghavi P; Holmes DR; Silberman H; Lagios M
    Am J Surg; 2006 Oct; 192(4):420-2. PubMed ID: 16978941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast.
    Hoque A; Lippman SM; Boiko IV; Atkinson EN; Sneige N; Sahin A; Weber DM; Risin S; Lagios MD; Schwarting R; Colburn WJ; Dhingra K; Follen M; Kelloff GJ; Boone CW; Hittelman WN
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):249-59. PubMed ID: 11303595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late recurrence of ductal carcinoma in situ at the cutaneous end of surgical drainage following total mastectomy.
    Finkelstein SD; Sayegh R; Thompson WR
    Am Surg; 1993 Jul; 59(7):410-4. PubMed ID: 8391769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study of wide excision alone for ductal carcinoma in situ of the breast.
    Lagios MD; Page DL; Silverstein MJ
    J Clin Oncol; 2006 Aug; 24(23):3809-11; author reply 3811-2. PubMed ID: 16896011
    [No Abstract]   [Full Text] [Related]  

  • 29. DCIS test helps filter at-risk patients.
    Peres J
    J Natl Cancer Inst; 2012 Dec; 104(24):1853-5. PubMed ID: 23231977
    [No Abstract]   [Full Text] [Related]  

  • 30. Ductal carcinoma in situ arising in an epithelial inclusion within an axillary lymph node.
    Srinivasan B; Allan CP; Armes JE
    Pathology; 2007 Apr; 39(2):268-9. PubMed ID: 17454760
    [No Abstract]   [Full Text] [Related]  

  • 31. Ductal carcinoma in situ: a review of recent advances.
    Tang P; Hajdu SI; Lyman GH
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):63-7. PubMed ID: 17218854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery.
    Boland GP; Chan KC; Knox WF; Roberts SA; Bundred NJ
    Br J Surg; 2003 Apr; 90(4):426-32. PubMed ID: 12673743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer.
    Kamei M; Yamashita S; Tokuishi K; Hashioto T; Moroga T; Suehiro S; Ono K; Miyawaki M; Takeno S; Yamamoto S; Kawahara K
    Anticancer Res; 2010 Nov; 30(11):4779-83. PubMed ID: 21115941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
    Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
    Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ductal carcinoma in situ: morphology-based knowledge and molecular advances.
    Ross DS; Wen YH; Brogi E
    Adv Anat Pathol; 2013 Jul; 20(4):205-16. PubMed ID: 23752083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with residual disease after initial breast-conserving surgery for ductal carcinoma in situ.
    Wei S; Kragel CP; Zhang K; Hameed O
    Hum Pathol; 2012 Jul; 43(7):986-93. PubMed ID: 22221704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ductal carcinoma in situ of the breast -- among factors predicting for recurrence, distance from the nipple is important.
    Stallard S; Hole DA; Purushotham AD; Hiew LY; Mehanna H; Cordiner C; Dobson H; Mallon EA; George WD
    Eur J Surg Oncol; 2001 Jun; 27(4):373-7. PubMed ID: 11417983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New method to predict DCIS recurrence.
    Printz C
    Cancer; 2013 Nov; 119(22):3899. PubMed ID: 24590902
    [No Abstract]   [Full Text] [Related]  

  • 39. Molecular profiling for DCIS.
    Russell CA
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):611-3. PubMed ID: 25654484
    [No Abstract]   [Full Text] [Related]  

  • 40. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score.
    Gwin K; Pinto M; Tavassoli FA
    Int J Surg Pathol; 2009 Aug; 17(4):303-10. PubMed ID: 19578051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.